

**IN THE CLAIMS**

Please amend the claims as follows:

Claims 1-17. (Cancelled)

18. (Currently Amended) [[A]] The medical device of claim 80 [[1]], wherein the medical device is a stent.
19. (Currently amended) [[A]] The medical device of claim 80 [[1]], wherein the first polymer covers all or a portion of the surface in a thickness of about 100 nm to 1 cm.
20. (Currently amended) [[A]] The medical device of claim 80 [[1]], wherein the first polymer covers all or a portion of the surface in a thickness of about 0.5  $\mu$ m to about 2.0 mm.
21. (Currently amended) [[A]] The medical device of claim 80 [[1]], wherein the salicylic acid ~~active agent~~ is disassociated from the first polymer over a period of about 2 days to about 2 years.

Claims 22-29 (Cancelled)

30. (Currently Amended) A medical device of claim 80 [[22]], wherein a third active agent is dispersed within the polymer matrix of the first polymer such that the third active agent is released upon degradation of the first polymer.

Claim 31. (Cancelled)

32. (Currently Amended) A medical device of claim 80 [[22]], wherein a third active agent is appended to the first polymer such that the third active agent is released under physiological conditions.

Claims 33-39 (Cancelled)

40. (Currently Amended) A stent of claim 18 ~~[[39]]~~, comprising at least two or more surfaces.
41. (Original) A stent of claim 40, wherein all or a portion of the two or more surfaces are covered with the first polymer.

Claims 42-51 (Cancelled)

52. (Currently Amended) The medical device of claim 80 ~~A stent of claim 39~~, wherein a second active agent is appended to the first polymer such that the second active agent is released under physiological conditions.

Claims 53-55 (Cancelled)

56. (Currently Amended) A stent of claim 41 ~~39~~, wherein the first polymer covers all or a portion of the surface in a thickness of about 100 nm to 1 cm.
57. (Currently Amended) A stent of claim 41 ~~39~~, wherein the first polymer covers all or a portion of the surface in a thickness of about 0.5  $\mu$ m to about 2.0 mm.
58. (Currently Amended) A stent of claim 41 ~~39~~, wherein the active agent is disassociated from the first polymer over a period of about 2 days to about 2 years.

59-79. (Canceled)

80. (Previously Presented) A medical device stent having at least one surface, comprising: 1) a first polymer comprising salicylic acid incorporated into the polymer backbone on all or a portion of the surface, wherein the salicylic acid is disassociated from the polymer upon hydrolysis; and 2) a second active agent selected from paclitaxel and rapamycin that is

dispersed within the polymer matrix of the first polymer such that the second active agent is released upon degradation of the first polymer.

81. (Previously Presented) The device of claim 80 wherein the second agent is paclitaxel.
82. (Previously Presented) The device of claim 80 wherein the second agent is rapamycin.